Corbus Pharmaceuticals Holdings, Inc. (CRBP) financial statements (2020 and earlier)

Company profile

Business Address 100 RIVER RIDGE DRIVE
NORWOOD, MA 02062
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments55426315126
Cash and cash equivalents55426315126
Restricted cash and investments  00  
Receivables   1  
Prepaid expense 2 100
Other undisclosed current assets3 30  
Total current assets:58446617137
Noncurrent Assets
Operating lease, right-of-use asset6
Property, plant and equipment531000
Restricted cash and investments   000
Other noncurrent assets000   
Total noncurrent assets:1131000
TOTAL ASSETS:68476718137
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities30168721
Accounts payable663310
Accrued liabilities24105310
Debt000000
Deferred rent credit 0
Deferred revenue and credits 22 
Contract with customer, liability1
Total current liabilities:31188941
Noncurrent Liabilities
Long-term debt and lease obligation8     
Operating lease, liability8
Liabilities, other than long-term debt 1100 
Deferred revenue and credits100 
Deferred rent credit 1
Other liabilities  00  
Total noncurrent liabilities:81100 
Total liabilities:38199941
Stockholders' equity
Stockholders' equity attributable to parent, including:302858996
Common stock000000
Common stock, share subscribed but unissued, subscriptions receivable   (0)  
Additional paid in capital196149123422210
Accumulated deficit(166)(121)(66)(33)(13)(4)
Other undisclosed stockholders' equity attributable to parent   0  
Total stockholders' equity:302858996
TOTAL LIABILITIES AND EQUITY:68476718137

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:355221 
Operating expenses(103)(62)(35)(22)(10)(3)
Operating loss:(68)(57)(33)(20)(9)(3)
Nonoperating income (expense)510(0)00
Investment income, nonoperating    00
Foreign currency transaction gain (loss), before tax(0)0(0)(0)00
Other nonoperating income4     
Interest and debt expense(0) (0)(0)(0)0
Other undisclosed income from continuing operations before equity method investments, income taxes0     
Net loss:(62)(56)(32)(20)(9)(2)
Other undisclosed net income (loss) attributable to parent0 000(0)
Net loss available to common stockholders, diluted:(62)(56)(32)(20)(9)(3)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(62)(56)(32)(20)(9)(2)
Comprehensive loss, net of tax, attributable to parent:(62)(56)(32)(20)(9)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: